![Andrea James](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 1 M $ in data 31/05/2026
Andrea James is Chief Financial Officer at Insight Molecular Diagnostics, Inc. since 2024.
Formerly, Ms. James was Vice President at Colliers Securities LLC and Chief Communications Officer at Axon Enterprise, Inc. from 2022 to 2023.
Ms. James completed undergraduate studies at American University and graduate studies at Northwestern University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 27/04/2026 | 206.060 ( 0,72% ) | 1 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| INSIGHT MOLECULAR DIAGNOSTICS INC. | Direttore Finanziario/CFO | 17/06/2024 |
| Società | Posizione | Fine |
|---|---|---|
| AXON ENTERPRISE, INC. | Contatto Relazioni con gli Investitori | 27/09/2022 |
Colliers Securities LLC
 Colliers Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Axon Enterprise, Inc.
 Axon Enterprise, Inc. Aerospace & DefenseElectronic Technology Develops and manufactures advanced conducted electrical weapons and software | Electronic Technology |
Colliers Securities LLC
Colliers Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
American University
 American University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoCyte Corp.
 OncoCyte Corp. BiotechnologyHealth Technology Focuses on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
